Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the screening of the first patient in a Phase 2b trial of MIN-117 (Study MIN-117C03) to reduce the symptoms of patients diagnosed with major depressive disorder (MDD).
The primary objective of the trial is to evaluate the efficacy of two fixed doses of MIN-117, 5.0 milligrams (mg) and 2.5 mg, compared with placebo in reducing the symptoms of major depression as measured by the change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score over six weeks of treatment. Secondary objectives include: (1) assessment of the change from baseline in symptoms of anxiety using the Hamilton Anxiety Scale (HAM-A); (2) the change in severity of illness using the Clinical Global Impression of Severity Scale (CGI-S) and Clinical Global Impression of Improvement Scale (CGI-I); and (3) safety over six weeks of treatment.
"While existing therapies for MDD are available, their effectiveness is limited due to unacceptable side effects, particularly cognitive impairment and sexual dysfunction," said Dr. Remy Luthringer, Chief Executive Officer of Minerva. "These shortcomings warrant the exploration of new treatment strategies with molecules such as MIN-117 that possess an innovative and rich pharmacological profile. In addition to the primary endpoint of reducing the symptoms of major depression, we plan to assess anxiety, cognition, sexual function, sleep, validated depression biomarkers and onset of action to further define the product profile of MIN-117 as an agent that can potentially address these shortcomings."
The study population will consist of adults with a diagnosis of moderate or severe MDD with anxious distress and without psychotic features. Based upon previous clinical observations, the Company believes that patients with MDD who also have symptoms of anxiety may benefit from treatment with MIN-117.
Approximately 324 patients are expected to be enrolled at approximately 40 sites in the U.S. and Europe. Patients will be randomized to one of three arms, including placebo and the two dosage arms, in a 2:1:1 ratio, resulting in approximately 162 patients in the placebo group and 81 patients in each of the two MIN-117 treatment groups. The study design includes a screening phase of up to three weeks, a six-week double-blind treatment phase and a two-week post-study follow-up period. Top line results of the trial are expected in the first half of 2019.
The pharmacological effects of MIN-117 are related to serotonin and dopamine, two neurotransmitters in the brain. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. When 5-HT1A is blocked, anxiety and mood can be regulated. In addition, MIN-117 is meant to prevent the reuptake of serotonin and dopamine, which increases the amount of serotonin and dopamine in the brain, which is tied to an improvement in mood in individuals suffering from MDD. MIN-117 is also meant to modulate the levels of Alpha-1a and 1b, which further modulates serotonin and dopamine.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva's proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and MDD; MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the Nasdaq Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with MIN-117; the timing and scope of future clinical trials and results of clinical trials with this compound; the clinical and therapeutic potential of this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-117 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether MIN-117 will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 12, 2018. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
HotDocs Wins Prestigious Queen's Award for Enterprise for International Trade26.4.2018 09:01 | Pressmeddelande
EDINBURGH, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- HotDocs, the global leader in document automation software powered by AbacusNext, has been named a winner of the 2018 Queen's Awards for Enterprise, the UK's highest accolade for business success. HotDocs received the award for achievement in International Trade in recognition of thriving overseas growth, accounting for an over seventy percent increase in revenue in the last three years. Since 1965, the Queen's Awards have recognised exceptional UK businesses who excel at international trade, innovations, or sustainable development-they are the highest official UK awards for enterprise excellence. HotDocs will be attending a reception at Buckingham Palace where Prince Charles will present the award on behalf of Her Majesty the Queen. This is HotDoc's second Queen's Award for Enterprise, the first was in 2013, also for excellence in International Trade. "We are proud to have been named a Queen's Award winner for the second ti
Historic GSA Meeting Forges Path for Blockchain Technology in Gaming Industry26.4.2018 09:00 | Pressmeddelande
LONDON, April 26, 2018 (GLOBE NEWSWIRE) -- The Gaming Standards Association's (GSA) recently formed Blockchain Technical Committee held its first meeting in London recently, charting a course to integrate the breakthrough technology into the gaming industry, with the potential to modernize lotteries and online and land-based gaming. The meeting was hosted by Playtech and attending were representatives from member companies, AxesNetwork, ComTrade Gaming, Gaming Laboratories International, Mercury Gaming Gauselmann, IGT, and Scientific Games. The topics of discussion included responsible gaming, machine certification, and jurisdictional licensing. "The spirit of collaboration among the members of this committee was groundbreaking, as everyone understands the mission critical responsibilities for the future of the global gaming industry," said Blockchain Committee Chair Earle G. Hall. "The enthusiasm and understanding of the task of the committee were infectious, and by the end of the day
SmartCash Highlights 2018 Initiatives to Accelerate Global Adoption, Recaps Key Achievements26.4.2018 09:00 | Pressmeddelande
Roadmap milestones focus on further scalability, merchant adoption, security and support NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- SmartCash, a community governance, cooperation and growth focused crypto-asset created via blockchain technology, today provides an overview of its recent achievements and ambitions for the year ahead. Self-funded, Merchant-Centric, Community-Driven and Easy to Use Recent accomplishments have positioned SmartCash to become the ideal choice for making payments anywhere in the world by introducing the following: Username-based addresses vs. highly complex addresses of Bitcoin and other cryptocurrencies Self-funded model to ensure continual development and outreach Transaction fees of less than 1/10th a cent Advanced governance system to give every SmartCash holder a voice SmartNodes to enable InstantPay and other future services Easy-to-use web wallet and mobile app To learn more about SmartCash's innovations, visit https://smartcash.cc/
Medibio Announces Scientific Advisory Board26.4.2018 06:00 | Pressmeddelande
Led by Board of Director Franklyn Prendergast, M.D., Ph.D. and Chief Medical Officer Archie Defillo, M.D. Key external members include Martin Chapman, M.D.; Joel Ehrenkranz, M.D.; Mark A. Frye, M.D.; Lawrence Hunter, Ph.D.; Wallace Mendelson, M.D.; Marie Casey Olseth, M.D., and Giampaolo Perna, M.D., Ph.D. SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB). Scientific Advisory Board Charter/Purpose The Medibio Scientific Advisory Board is charged to advise the board of directors and executive leadership team on scientific matters involving the Company's discovery and development of programs, including major internal projects, interactions with academic and other outside research organizations, and the acquisition of technologies. The SAB will assist directors and management to stay abreast of industry and menta
Madison Realty Capital Provides $35 Million Mezzanine Loan for 611 West 56th Street Condominium Development in Hell's Kitchen26.4.2018 00:51 | Pressmeddelande
Part of Overall $155 Million Financing Package Provided by MRC and Apollo Global Management for Planned 35 Story Condo Tower at 56th Street and Eleventh Avenue First New York City Project Designed by Renowned Architect Álvaro Siza NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Madison Realty Capital (MRC) provided a $35 million mezzanine loan to co-developers Sumaida + Khurana and LENY for a new condominium tower located at 611 West 56th Street in the Hell's Kitchen neighborhood of Manhattan. The funding is part of a $155 million construction financing package for the project provided by MRC and an investment fund managed by Apollo Global Management. Located in the evolving Hudson West neighborhood, 611 West 56th Street will stand 35 stories in height, encompass 163,329 square feet and feature 83 residences, ranging from one-bedrooms to expansive penthouses. The condominium will also feature a significant amount of outdoor space, including a landscaped roof garden and sun deck, as well a
Crocus Technology Raises $35M in Financing26.4.2018 00:36 | Pressmeddelande
Final round of financing to fuel Crocus' rapidly growing TMR magnetic sensor business SANTA CLARA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Crocus Technology, a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces it has secured $35M in funding through a combination of debt and equity from internal investors and external sources. The funding will enable Crocus Technology to accelerate its revenue growth by expanding its operations and go-to-market resources and by investing in the continuous development of innovative products to serve the demand of existing and emerging markets. Crocus' proprietary MLU(TM) technology enables its TMR sensor products to have high magnetic sensitivity with minimal variation over a wide temperature range, coupled with ultra-low power consumption, which makes them ideal sensing solutions for IoT, mobile, automotive, medical and industrial applications. Crocus' TMR integrated sensor products are embedded within a CMOS pro
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum